{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T15:25:15Z","timestamp":1692890715714},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.8706-16","type":"journal-article","created":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T22:10:11Z","timestamp":1502316611000},"page":"2335-2338","source":"Crossref","is-referenced-by-count":4,"title":["Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis"],"prefix":"10.2169","volume":"56","author":[{"given":"Megumi","family":"Koshiishi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Sueki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Mitsumori","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799-807, 2012.","DOI":"10.1056\/NEJMoa1110557"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787-798, 2012.","DOI":"10.1056\/NEJMoa1110556"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372: 426-435, 2015.","DOI":"10.1056\/NEJMoa1409002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mesa RA, Komrokji RS, Verstovsek S. Ruxolitinib dose management as a key to long-term treatment success. Int J Hematol 104: 420-429, 2016.","DOI":"10.1007\/s12185-016-2084-1"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122: 3843-3844, 2013.","DOI":"10.1182\/blood-2013-10-531103"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 86: 1188-1191, 2011.","DOI":"10.4065\/mcp.2011.0518"},{"key":"7","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"7. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90: 1128, 2005.","journal-title":"Haematologica","ISSN":"http:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Komatsu N, Kirito K, Shimoda K, et al. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. Int J Hematol 105: 309-317, 2017.","DOI":"10.1007\/s12185-016-2130-z"},{"key":"9","unstructured":"9. Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149: 578-586, 2010."},{"key":"10","unstructured":"10. TLS guidance. Japanese Society of Medical Oncology, Ed. Kanehara-shuppan, Tokyo, 2013."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 364: 1844-1854, 2011.","DOI":"10.1056\/NEJMra0904569"},{"key":"12","unstructured":"12. Hentrich M, Rockstroh J, Sandner R, Brack N, Hartenstein R. Acute myelogenous leukaemia and myelomonocytic blast crisis following polycytemia vera in HIV positive patients: report of cases and review of the literature. Ann Oncol 11: 195-200, 2000."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Ellis AK, Lee DH. Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera. Am J Hematol 71: 237-238, 2002.","DOI":"10.1002\/ajh.10220"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Jain S, Harrison C, McMullin MF, Houston RF. Tumour lysis syndrome after splenic irradiation in a patient with JAK2 V617F post-polycythaemia vera myelofibrosis. Clin Oncol 22: 893, 2010.","DOI":"10.1016\/j.clon.2010.07.002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Cvetkovi\u0107 ZP, Cvetkovi\u0107 BR, \u010celeketi\u0107 D, Milenkovi\u0107 D, Peruni\u010di\u0107-Pekovi\u0107 G. Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia. Acta Chirurgica Iugoslavica 57: 79-83, 2010.","DOI":"10.2298\/ACI1002079C"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Dai T, Friedman EW, Barta SK. Ruxolitinib withdrawal syndrome leading to tumor lysis. J Clin Oncol 31: e430-e432, 2013.","DOI":"10.1200\/JCO.2012.47.6473"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sile S, Wall BM. Acute renal failure secondary to spontaneous acute tumor lysis syndrome in myelofibrosis. Am J Kidney Dis 38: e21.1-e.4, 2001.","DOI":"10.1053\/ajkd.2001.27730"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sonmez M, Ovali E, Omay SB. Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase. J Clin Pharm Ther 33: 91-92, 2008.","DOI":"10.1111\/j.1365-2710.2008.00873.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Al-Kali A, Farooq S, Tfayli A. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. J Clin Pharm Ther 34: 607-610, 2009.","DOI":"10.1111\/j.1365-2710.2009.01035.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Hua J, Iwaki Y, Inoue M, Hagihara M. Tumor lysis syndrome soon after treatment with hydroxyurea followed by nilotinib in two patients with chronic-phase chronic myelogenous leukemia. Int J Hematol 98: 243-246, 2013.","DOI":"10.1007\/s12185-013-1356-2"},{"key":"21","unstructured":"21. Chen SW, Hwang WS, Tsao CJ, Liu HS, Huang GC. Hydroxyurea and splenic irradiation-induced tumour lysis syndrome: a case report and review of the literature. J Clin Pharm Ther 30: 623-625, 2005."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/17\/56_8706-16\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T05:59:42Z","timestamp":1569995982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/17\/56_8706-16\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8706-16","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}